ATE401889T1 - Verwendung von trioxopyrimidin zur behandlung und prävention von entzündlichen erkrankungen der bronchien - Google Patents

Verwendung von trioxopyrimidin zur behandlung und prävention von entzündlichen erkrankungen der bronchien

Info

Publication number
ATE401889T1
ATE401889T1 AT05734016T AT05734016T ATE401889T1 AT E401889 T1 ATE401889 T1 AT E401889T1 AT 05734016 T AT05734016 T AT 05734016T AT 05734016 T AT05734016 T AT 05734016T AT E401889 T1 ATE401889 T1 AT E401889T1
Authority
AT
Austria
Prior art keywords
mmp
sub
prevention
treatment
inflammatory diseases
Prior art date
Application number
AT05734016T
Other languages
English (en)
Inventor
Didier Cataldo
Luc Delattre
Brigitte Evrard
Jean-Michel Foidart
Hans-Willi Krell
Original Assignee
Hoffmann La Roche
Univ Liege
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Univ Liege filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE401889T1 publication Critical patent/ATE401889T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT05734016T 2004-04-01 2005-03-31 Verwendung von trioxopyrimidin zur behandlung und prävention von entzündlichen erkrankungen der bronchien ATE401889T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04007920 2004-04-01

Publications (1)

Publication Number Publication Date
ATE401889T1 true ATE401889T1 (de) 2008-08-15

Family

ID=34924546

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05734016T ATE401889T1 (de) 2004-04-01 2005-03-31 Verwendung von trioxopyrimidin zur behandlung und prävention von entzündlichen erkrankungen der bronchien

Country Status (13)

Country Link
US (1) US20070225253A1 (de)
EP (1) EP1737464B1 (de)
JP (1) JP4584981B2 (de)
CN (1) CN100558362C (de)
AT (1) ATE401889T1 (de)
AU (1) AU2005230379B2 (de)
BR (1) BRPI0509562A (de)
CA (1) CA2561828C (de)
DE (1) DE602005008418D1 (de)
ES (1) ES2311220T3 (de)
MX (1) MXPA06011030A (de)
RU (1) RU2402329C2 (de)
WO (1) WO2005097133A1 (de)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548624A1 (de) * 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
CN1133643C (zh) * 1995-12-29 2004-01-07 葛兰素集团有限公司 17-β-羧基,羰基硫代以及酰胺雄甾烷衍生物的内酯衍生物
AU746853B2 (en) * 1997-06-21 2002-05-02 Roche Diagnostics Gmbh Barbituric acid derivatives with antimetastatic and antitumor activity
DE19726427A1 (de) * 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
RU2188201C2 (ru) * 1997-11-19 2002-08-27 Ашкинази Римма Ильинична Производные 5h-пирано[2,3-d:6,5-d']дипиримидина, обладающие антимикробным, противовирусным и иммуномодулирующим действием
FI990888A0 (fi) * 1999-04-20 1999-04-20 Medix Biochemica Ab Oy Menetelmä ja testikittejä respiratorisen alueen tulehduksen läsnäolon ja vaikeusasteen arvioimiseksi
RU2170091C2 (ru) * 1999-07-27 2001-07-10 Всероссийский научный центр по безопасности биологически активных веществ Антиаллергическое и противовоспалительное средство
AR033651A1 (es) * 1999-10-01 2004-01-07 Hoffmann La Roche Derivados de pirimidina-2,4,6-triona, composiciones farmaceuticas que contienen dichos compuestos y el empleo de los mismos para la manufactura de un medicamento
IL154946A0 (en) * 2000-10-26 2003-10-31 Pfizer Prod Inc Pyrimidine-2,4,6-trione metalloproteinase inhibitors
BR0114913A (pt) * 2000-10-26 2003-07-01 Pfizer Prod Inc Inibidores de metaloproteinase de espiro-pirimidina-2,4,6-triona

Also Published As

Publication number Publication date
AU2005230379B2 (en) 2010-07-22
CN100558362C (zh) 2009-11-11
JP4584981B2 (ja) 2010-11-24
WO2005097133A1 (en) 2005-10-20
CN1950087A (zh) 2007-04-18
MXPA06011030A (es) 2007-03-21
BRPI0509562A (pt) 2007-09-25
EP1737464A1 (de) 2007-01-03
RU2006138430A (ru) 2008-06-10
CA2561828C (en) 2012-05-22
AU2005230379A1 (en) 2005-10-20
RU2402329C2 (ru) 2010-10-27
JP2007530625A (ja) 2007-11-01
US20070225253A1 (en) 2007-09-27
DE602005008418D1 (de) 2008-09-04
CA2561828A1 (en) 2005-10-20
EP1737464B1 (de) 2008-07-23
ES2311220T3 (es) 2009-02-01

Similar Documents

Publication Publication Date Title
ATE548354T1 (de) Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
NL300933I2 (nl) Letermovir
WO2006113942A3 (en) Method of inhibiting cathepsin activity
NO20070526L (no) Kinazolindionderivater som parp-inhibitorer
ATE523196T1 (de) Mitotische kinesinhemmer und verfahren zu ihrer verwendung
NO20063479L (no) Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer
SE0201976D0 (sv) Novel compounds
DE60026155D1 (de) Einige alkylendiamin-substituierte heterocyclen
WO2004080422A3 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
WO2004106293A3 (en) Oxazolyl - and thiazolyl - purine based tricyclic compounds.
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
ATE349448T1 (de) Pyrazol-3,4-d-pyrimidinderivate und ihre verwendung bei der behandlung von h.pylori- infektionen
DK1532124T3 (da) Anvendelse af nitriderivater som medikament
NO20054494L (no) Peptidvektorer
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
ECSP055844A (es) Nuevos compuestos triciclicos
DE60329326D1 (de) Tace inhibitoren
WO2004075846A3 (en) Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
DE50310038D1 (de) Hemmstoffe der urokinase, ihre herstellung und verwendung
WO2005011609A3 (en) Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
WO2004060878A3 (en) Inhibitors of phosphatases
ATE401889T1 (de) Verwendung von trioxopyrimidin zur behandlung und prävention von entzündlichen erkrankungen der bronchien

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1737464

Country of ref document: EP

EEIH Change in the person of patent owner